BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange
Net sales ¥99.028b (YE 05) compared to ¥99.231b (YE 04)
Net income ¥1.409 (YE 05) compared to ¥2.372b (YE 04)
Earnings per share ¥10.04/share (YE 05) compared to ¥16.59/share (YE 04)
Total assets ¥87.939b (YE 05) compared to ¥90.616b (YE 04)
SUBSIDIARIES/DIVISIONS: Liquor Company
Processing Liquors Company
Pharmaceuticals & Chemicals Company
Feedstuffs Company
BUSINESS STRATEGY: Maintain position as a leading producer of alcholic beverages, and
manufactuer of feedstuffs, chemical products and pharmaceuticals
AGREEMENTS: Name Products Content of Agreement Date
ILEX Oncolgy NM-3 license agreement
RESEARCH & DEVELOPMENT: Screening new anticancer drugs and other chemical compounds produced
using microorganisms
Development of manufacturing processes for chiral compounds utilizing
bioconversion
Analysis of fermentation characteristics and aroma and taste
Breeding of new yeast genes
Study of liquor fermentation mechanisms
Examination of the health benefits of wine
Merck KGaA
Frankfurter Str. 250
Darmstadt D-64293, Germany
Phone: +49 6151-72-0; Fax: +49 6151-72-2000
Web: www.merck.de
E-mail: service@merck.de
KEY PERSONNEL: Dr. Michael Romer; Chairman
Karl-Ludwig Kley; Deputy Chairman
EMPLOYEES: 29,600 employees
HISTORY: Founded in 1668
FACILITIES: Production and/or sales operations in 54 countries
STOCK-FINANCIAL HISTORY: Reuters--MRCG / Bloomberg--MRK GY / FSE--ISIN: DE 00065 99905 -
WKN: 659 990
IPO--(1995)
Sales EUR5.870b (YE 05) compared to EUR5.340b (YE 04)
Earnings per share EUR0.85/share (YE 05) compared to EUR1.00/share
(YE 04)
SUBSIDIARIES/DIVISIONS: Pharmaceuticals Business Sector--divisions include Ethical
Pharmaceuticals, Generics, OTC
Chemicals Business Sector--divisions include Liquid Crystals, Performance
& Life Science
INVESTMENTS: Agribiotics Holdings Inc. in 3/06
Survac ApS in 11/05
Lumitec OLED R&D project of Schott AG in 2/05
OLED materials (Covion Organic Semiconductors GmbH) and polymer
electronics businesses fron Avecia in 4/05
BUSINESS STRATEGY: Focus on business segments in which the company achieves competitive
advantages through excellent quality of products, services and systems by
concentrating on innovations and research in the pharmaceuticals business
and on higher grade products in the chemicals business
Copyright ©2006 AHC Media ® 239